Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Express Co (AXP) vs Becton Dickinson and Co (BDX) Price & Performance

American Express CoTrade
Becton Dickinson and CoTrade

Price performance (Past 24H)

Key statistics

American Express Co vs Becton Dickinson and Co — how do they compare? American Express Co trades at $340.93 (market cap $230.15B), while Becton Dickinson and Co trades at $180.34 (market cap $49.41B). The key difference: American Express Co is far larger — about 4.7× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.32%). Which is the better fit depends on your goals.

AXPBDX
Market Cap
$230.15B$49.41B
Sector
FinancialsHealth
52-Week High
$384.82$185.39
52-Week Low
$292.27$138.62
Dividend Yield
1.11%2.32%
Enterprise Value
$65.51B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Express Co

American Express (AXP) trades at $338.86, down 0.6% with bearish technical signals despite strong fundamentals. The company reported solid Q2 2026 earnings beat ($4.53 vs $4.41 expected) and maintains robust profitability with 15.07% net margin and 33.97% ROE. Recent news highlights Amex Ventures' AI investments and premium card member experiences, while Berkshire Hathaway's 20% ownership underscores long-term confidence in the business model.

AXP presents a mixed outlook with strong fundamental performance offset by technical weakness. The stock offers 9% upside to consensus price target of $369.42, supported by revenue growth and premium positioning, but faces headwinds from bearish technical indicators and competitive pressure in digital payments. Risk-reward appears balanced near current levels.

Becton Dickinson and Co

BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.

The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Express Co

American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.

Read more on AXP

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX